[抗脂综合征患者的临床行为和治疗状况]
Yanyan Li1,2, Xiangjun Liu1, Gongming Li1,3
1Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing 100044, China.
概括
抗脂综合征 (APS) 患者经常面临诊断延迟,体验较差的健康状况和更高的焦虑比健康人群. 强调定期的随访和精神教育支持对于有效管理APS至关重要.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 抗脂综合征 (APS) 是一种与血栓事件和妊娠并发症相关的自身免疫性疾病.
- 了解APS患者的临床行为和治疗状况对于改善患者的治疗结果至关重要.
研究的目的:
- 调查和分析被诊断患有抗脂综合征 (APS) 的患者的临床行为和治疗状态.
主要方法:
- 分析了196名在2021年9月至2025年10月期间被诊断为APS患者的队列.
- 数据包括人口统计,疾病特征,诊断时间表,治疗和通过SF-36,HADS和GMAS的健康状况.
- 年龄和性别匹配的健康对照接受了SF-36和HADS评估.
主要成果:
- APS发病的中位数年龄为36岁,女性占主导地位 (比例为1.6.8).
- 观察到显著的诊断延迟,有32.1%的患者经历了超过一年的延迟.
- 与健康对照组相比,APS患者的整体健康评分 (SF-36) 较低,焦虑症状 (HADS) 较高.
结论:
- 延迟诊断仍然是抗脂综合征 (APS) 管理的一个挑战.
- 患有APS的患者表现出身体功能受损和焦虑增加,需要集中干预.
- 建议定期进行随访和心理教育支持,以获得最佳的患者护理.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
221
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
221
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
318
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
318
Venous Thrombosis IV: Nursing Management
182
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
182
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
434
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
434

